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Summary
Background Hyperbaric oxygen has been used as a therapy for patients experiencing chronic intestinal syndromes after 
pelvic radiotherapy for decades, yet the evidence to support the use of this therapy is based almost exclusively on 
non-randomised studies. We aimed to provide conclusive results for the clinical benefi ts of hyperbaric oxygen in patients 
with chronic bowel dysfunction after radiotherapy for pelvic malignancies.
Methods HOT2 was a double-blind, sham-controlled, phase 3 randomised study of patients (≥18 years) with chronic 
gastrointestinal symptoms for 12 months or more after radiotherapy and which persisted despite at least 3 months of 
optimal medical therapy and no evidence of cancer recurrence. Participants were stratifi ed by participating hyperbaric 
centre and randomly assigned (2:1) by a computer-generated list (block size nine or 12) to receive treatment with 
hyperbaric oxygen therapy or sham. Participants in the active treatment group breathed 100% oxygen at 2∙4 atmospheres 
of absolute pressure (ATA) and the control group breathed 21% oxygen at 1∙3 ATA; both treatment groups received 
90-min air pressure exposures once daily for 5 days per week for a total of 8 weeks (total of 40 exposures). Staff  at the 
participating hyperbaric medicine facilities knew the allocated treatment, but patients, clinicians, nurse practitioners, 
and other health-care professionals associated with patients’ care were masked to treatment allocation. Primary 
endpoints were changes in the bowel component of the modifi ed Infl ammatory Bowel Disease Questionnaire (IBDQ) 
score and the IBDQ rectal bleeding score 12 months after start of treatment relative to baseline. The primary outcome 
was analysed in a modifi ed intention-to-treat population, excluding patients who did not provide IBDQ scores within a 
predetermined time-frame. All patients have completed 12 months of follow-up and the fi nal analysis is complete. 
The trial is registered with the ISRCTN registry, number ISRCTN86894066.
Findings Between Aug 14, 2009, and Oct 23, 2012, 84 participants were randomly assigned: 55 to hyperbaric oxygen and 
29 to sham control. 75 (89%) participants received 40 pressure exposures, all participants returned the IBDQ at baseline, 
75 (89%) participants returned the IBDQ at 2 weeks post-treatment, and 79 (94%) participants returned the IBDQ at 
12 months post-start of treatment. Patients were excluded from analyses of co-primary endpoints if they had missing IBDQ 
scores for intestinal function or rectal bleeding at baseline or at 12 months. In an analysis of 46 participants in the active 
treatment group and 23 participants in the control group, we found no signifi cant diff erences in the change of IBDQ bowel 
component score (median change from baseline to 12 months of 4 (IQR –3 to 11) in the treatment group vs 4 (–6 to 9) in the 
sham group; Mann-Whitney U score 0∙67, p=0∙50). In an analysis of 29 participants in the active treatment group and 
11 participants in the sham group with rectal bleeding at baseline, we also found no signifi cant diff erences in the change of 
IBDQ rectal bleeding score (median change from baseline to 12 months of 3 [1 to 3] in the treatment group vs 1 [1 to 2] in the 
sham group; U score 1∙69, p=0∙092). Common adverse events in both groups were eye refractive changes (three [11%] of 
28 patients in the control group vs 16 [30%] of 53 patients in the treatment group), increased fatigue (three [11%] vs two [4%]), 
and ear pain (six [21%] vs 15 [28%]). Eight serious adverse events were reported in eight patients: two were reported in 
two patients in the control group (tonsillitis requiring surgery [grade 3]; recurrent cancer of the vulva [grade 4]) and six serious 
adverse events were reported in six patients in the treatment group (malignant spinal cord compression requiring surgery 
[grade 3]; malignant paraortic lymph node involvement requiring surgery [grade 3]; recurrence of vomiting and dehydration 
[grade 3]; diarrhoea and fever associated with Campylobacter infection [grade 3]; recurrence of abdominal pain, bloating, 
diarrhoea, and urinary tract infection [grade 3]; aneurysm [grade 4]), none of which were deemed treatment-related.
Interpretation We found no evidence that patients with radiation-induced chronic gastrointestinal symptoms, including 
those patients with rectal bleeding, benefi t from hyperbaric oxygen therapy. These fi ndings contrast with evidence used 
to justify current practices, and more level 1 evidence is urgently needed.
Funding Cancer Research UK and National Health Service (NHS) funding to the National Institute of Health Research 
Biomedical Research Centre at The Royal Marsden and the Institute of Cancer Research.
Copyright © Glover et al. Open Access article distributed under the terms of CC BY.
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Introduction
More than 1 million patients worldwide are estimated to 
need curative radiotherapy for pelvic cancer annually, 
with up to a third of these patients subsequently 
developing chronic moderate or severe gastrointestinal 
symptoms.1 Hyperbaric oxygen has been used as a 
therapy for symptomatic patients for decades, yet the 
evidence to support the use of this therapy is based 
almost exclusively on non-randomised studies.2 The 
authors of a 2012 Cochrane intervention review3 
identifi ed a single well designed, controlled, randomised 
trial (HORTIS)4 that showed clinical benefi t of hyperbaric 
oxygen therapy in patients with gastrointestinal 
symptoms after radiotherapy for cancers of the colon, 
endometrium, uterine corpus, uterine cervix, prostate, or 
rectum. We conducted a double-blind, randomised 
controlled trial (HOT2) to test long-term benefi ts of 
hyperbaric oxygen therapy in patients with chronic 
adverse eff ects of curative pelvic radiotherapy after failure 
of optimum medical therapy for symptoms of pelvic 
radiation disease.
Methods
Study design and participants
The HOT2 trial was a randomised, double-blind, 
sham-controlled phase 3 study involving ten UK 
hyperbaric medicine facilities registered with the British 
Hyperbaric Association (appendix p 2).
Eligible participants were men and women aged 
18 years or older with at least grade 2 gastrointestinal 
symptoms in any category of the Late Eff ects Normal 
Tissue scoring system (LENT SOMA) for radiation injury 
or grade 1 gastrointestinal symptoms with intermittent 
symptoms attributed to radiotherapy for carcinoma of the 
rectum, prostate, testis, bladder, uterine cervix, uterine 
corpus, vagina, vulva, or ovary for at least 12 months 
before enrolment. Grade 2 symptoms defi ned by LENT 
SOMA are moderate, requiring only conservative 
treatment, whereas grade 3 symptoms are severe, having 
a substantial negative eff ect on daily activities, and 
necessitating more aggressive treatment.5 Participants 
were screened for eligibility if they presented with 
gastrointestinal symptoms such as onset or worsening of 
anal, rectal, atypical abdominal, or back pain; endoscopic 
evidence of anal, rectal, or sigmoid stricture; worsening 
of intestinal symptoms after months or years of stable 
symptoms; worsening of urinary symptoms; or new 
vaginal bleeding. Potentially eligible participants were 
assessed using a clinical algorithm6 to identify individuals 
with symptoms attributable to radiotherapy. Eligible 
patients could show no evidence of cancer recurrence, as 
assessed by magnetic resonance imaging of the pelvis, 
abdomen, and spine. Additional exclusion criteria 
included medical history of cancer recurrence, rectal 
surgery, previous hyperbaric oxygen therapy (except 
for treatment of decompression illness), exposure 
to bleomycin, claustrophobia, epilepsy, uncontrolled 
asthma, bullous lung disease, some types of ear surgery, 
and inability to equalise the middle ear. Individuals with a 
past history of prostate cancer had to have three serial 
measurements of serum prostate-specifi c antigen within 
the normal concentration range (less than 3 ng/mL for 
men aged 50–59 years, 4 ng/mL for men aged 60–69 years, 
5 ng/mL for men 70 years or older).
Patients with symptoms attributed to radiotherapy 
entered a minimum 3-month period of optimum standard 
treatment, including antibiotic treatment for small bowel 
bacterial overgrowth, treatment of bile acid malabsorption,7 
lifestyle advice, or several of these interventions, and were 
supervised by a gastroenterologist. Individuals were 
considered eligible for the study only if the 3-month 
period of optimal standard treatment was unsuccessful.
Research in context
Evidence before this study
Hyperbaric oxygen is widely used to treat chronic adverse 
eff ects of curative radiotherapy in long-term survivors of 
pelvic malignancy, especially those with rectal bleeding. We 
searched PubMed from Jan 1, 1970, to Dec 31, 2008, with the 
terms “clinical trials” AND “hyperbaric oxygen” AND “pelvic” 
OR “pelvis” OR “bowel” AND radiotherapy”. We identifi ed 
11 relevant publications, including reviews, relatively small 
case studies, and case reports. The results of a single 
randomised, sham-controlled trial from 2008 (HORTIS) 
reported signifi cant clinical benefi ts for patients treated with 
hyperbaric oxygen 2 weeks post-treatment. A Cochrane 
intervention review from 2012 confi rmed the retrospective 
nature of much research and detected no other level 1 
evidence on which to base an assessment of this treatment 
modality for patients with chronic radiation-induced bowel 
dysfunction.
Added value of this study
The results of this double-blind, sham-controlled clinical trial fail 
to confi rm earlier positive results of hyperbaric therapy for 
cancer survivors with chronic bowel dysfunction, including a 
subset of patients with rectal bleeding, after curative 
radiotherapy for pelvic malignancy, with a similarly sized 
minority of volunteers in each randomised group reporting 
some improvement in symptoms. This trial is only the second 
randomised study in this important patient population.
Implications of all the available evidence
The contribution of hyperbaric oxygen to the management of a 
growing population of long-term cancer survivors with severe 
restrictions on daily activities and impaired quality of life as a 
consequence of bowel injuries after curative radiotherapy for 
pelvic malignancy remains unclear and requires more evidence 
from well designed clinical trials. 
See Online for appendix
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All patients provided written informed consent. We 
listed no criteria for removing a patient from the trial once 
written informed consent was gained. The study was 
approved by the MHRA (2008-002152-26) and the NRES 
Committee North East-York (08/H0903/40). The full case 
study report and trial protocol are available online.
Randomisation and masking
Eligible participants were randomly assigned (2:1) 
to receive hyperbaric oxygen treatment or sham. 
Randomisation was arranged by a telephone call from 
the treating hyperbaric medicine facility to the Institute 
of Cancer Research Clinical Trials and Statistics Unit 
(ICR-CTSU). Randomisation was by computer-generated 
random permuted blocks (block size of nine and 12), and 
participants were stratifi ed by centre. Computer-generated 
lists were used to allocate patients within a block. 
To deliver the correct treatment, only engineers and 
technicians operating the hyperbaric chamber were 
informed of the allocated treatment by the trials offi  ce, 
and care was taken to ensure that patients, clinicians, 
nurse practitioners, and other health-care professionals 
associated with patients’ care remained masked to 
treatment allocation. The most important precaution was 
to disallow any non-trial patient sharing the chamber 
with a trial patient.
Procedures
Participants attended the participating hyperbaric oxygen 
medicine facility most convenient for them, where they 
were assessed for suitability for hyperbaric oxygen therapy. 
Patients in the hyperbaric oxygen therapy group received 
40 pressure exposures at 2∙4 atmospheres of absolute 
pressure (ATA; 243 kPa) breathing 100% oxygen for 
90 min (including 5-min air breaks at 30-min intervals), 
whereas patients in the control group received 40 pressure 
exposures at 1∙3 ATA (131 kPa) breathing 21% oxygen 
(ie, air) for 90 min with two simulated 5-min air breaks. 
We aimed to deliver the pressure exposures once a day for 
5 days per week for 8 weeks for a total of 40 pressure 
exposures. Additional treatments were delivered beyond 
the 8-week timeframe if any scheduled sessions were 
missed. Dose reductions were not permitted.
Participants were asked to complete the modifi ed 
Infl ammatory Bowel Disease Questionnaire (IBDQ)8 and 
the European Organisation for Research and Treatment of 
Cancer (EORTC) C30 core quality of life questionnaire 
(QLQ-C30) and CR38 colorectal module (QLQ-CR38)9,10 
at baseline, 2 weeks after end of treatment, and again at 
3 months, 6 months, 9 months, and 12 months after start 
of treatment. At each timepoint, patients were asked to 
base their responses on symptoms experienced within the 
previous 2 weeks. The IBDQ bowel function component 
(panel) was adopted on the basis of previous application 
for the characterisation of chronic gastrointestinal 
morbidity after pelvic radiotherapy in a comparable 
population of former patients.8,12 Late radiation-induced 
adverse eff ects were clinically assessed within 2 weeks of 
treatment completion and again at 12 months after start of 
treatment and were based on the LENT SOMA intestinal 
and rectal scales of radiation injury (version 2) and 11 
questions selected from the Common Terminology 
Criteria for Adverse Events (CTCAE) gastrointestinal scale 
(version 4), which were considered most relevant to the 
study population.5,13 Telephone interviews were substituted 
for the minority of patients unable to attend appointments 
at the Royal Marsden as per protocol.
Outcomes
The two primary clinical endpoints of the study were the 
change in gastrointestinal symptoms score using the 
IBDQ and the change in rectal bleeding score (Question 22) 
in the IBDQ between baseline and 12 months (panel). 
Secondary clinical endpoints were adverse eff ects (bowel 
dysfunction) assessed according to LENT SOMA scales of 
radiation injury, clinical assessments of gastrointestinal 
symptoms according to the 11 questions selected from the 
CTCAE gastrointestinal scale (version 4), and patient 
self-assessments of quality of life recorded by the EORTC 
QLQ-C30 core questionnaire and QLQ-CR38 colorectal 
module between baseline and 12 months.
Statistical analysis
The sample size was calculated on the basis of the bowel 
component of the modifi ed IBDQ primary endpoint. 
On the basis of results from a previous study,14 we 
considered a reduction in IBDQ bowel component 
Panel: Bowel function component of the modifi ed Infl ammatory Bowel Disease 
Questionnaire (IBDQ)11
Question 1: Have you had your bowel open?
Question 5: Have you had loose bowel movements?
Question 9: Have you been troubled by pain in your bottom?
Question 13: Have you had cramp in tummy or bottom?
Question 17: Have you passed a large amount of gas?
Question 20: Have you been troubled by bloating?
Question 22: Have you had a problem with bleeding from your bottom?
Question 24: Have you felt like you need to have your bowel open but nothing happens?
Question 26: Have you been troubled by accidental soiling?
Question 29: Have you felt disgusted about your bowel problems?
Each question is linked to the following response options on a 7-point graded scale: 1=more 
than ever before; 2=extremely frequently; 3=very frequently; 4=moderate increase in 
frequency; 5=some increase in frequency; 6=slight increase in frequency; 7=normal/not at 
all. The possible range of summed results for the 10 questions is 10–70, where 10 represents 
the most severe, and 70 the least severe, levels of eff ect, this metric represents a co-primary 
endpoint. Question 22, analysed separately, is the second co-primary endpoint.
For the study report see http://
www.ddrc.org/uploads/HOTII/
clinical-study-report.pdf
For the trial protocol see http://
www.ddrc.org/uploads/HOTII/
trial-protocol.pdf
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score of 7 (SD 10) from baseline to 12 months to be 
clinically relevant. To detect this minimum change at a 
two-sided signifi cance level of 5% and an estimated 
power of 80%, we planned to enrol 75 evaluable 
patients. During the recruitment phase of the trial 
(February, 2012), the independent data monitoring 
committee agreed that the signifi cance level of 5% 
could be split to allow additional analyses in patients 
reporting rectal bleeding in the IBDQ at baseline. We 
estimated that 75 evaluable patients would allow us to 
detect a diff erence in IBDQ bowel symptom score of 
7∙5 with 80% power at a two-sided signifi cance level 
of 3%. On the basis of the assumption that 30 of 
75 patients would report grade 2–4 rectal bleeding at 
baseline on the LENT SOMA Management Scale, 
corresponding to a score of 1–5 on the IBDQ rectal 
bleeding scale, this subgroup would allow us to detect a 
diff erence of 70% of patients showing any improvement 
in rectal bleeding (10% in the control group, 80% in the 
hyperbaric oxygen therapy group) with 80% power at a 
two-sided signifi cance level of 2%.
Analysis of primary endpoints was by modifi ed 
intention-to-treat, which included analysis of data from 
forms returned by patients within timeframes agreed to 
by the independent data monitoring committee. 
All patients who received any treatment (hyperbaric 
oxygen therapy or sham) were included in the safety 
population. Forms were processed as follow-up 
assessments according to the period that had elapsed 
between start of treatment and time of completion 
(table 1). IBDQ questions are scored from 1 to 7 with a 
low score indicating poorer function or worse 
symptoms. The bowel component is made up of ten 
questions, and we used all ten items in the bowel 
component of the modifi ed IBDQ to analyse overall 
bowel function and analysed rectal bleeding using the 
single rectal bleeding question in the modifi ed IBDQ. 
The diff erence in change from baseline to 12 months 
between the two study groups was analysed using the 
Mann-Whitney U test due to the non-normality of the 
data. We planned sensitivity analyses of the primary 
endpoints and the LENT SOMA secondary endpoint in 
the population of patients who were registered into the 
study and returned IBDQ forms, irrespective of 
timelines (intention-to-treat), and in the per-protocol 
population, which included all patients registered into 
the study who received at least 32 pressure exposures 
within a 10-week period. These sensitivity analyses 
excluded individuals who received less than three 
treatments per week for at least 2 weeks or who missed 
fi ve consecutive treatments.
For the comparison of change in LENT SOMA scores 
from baseline to 12 months for rectum and intestine 
(secondary endpoints; table 2) between the active 
treatment and control groups, we scored individual 
symptoms within each of three LENT SOMA descriptors 
(subjective, objective, management) using a four-point 
scale (with high scores denoting worse symptoms) and 
summed these scores to develop overall subjective, 
objective, and management scores for each anatomical 
site (rectum and intestine). We did no formal statistical 
analyses of other secondary endpoints (CTCAE 
scales, EORTC QLQ-C30, and QLQ-CR3810), although 
the descriptive results were used to strengthen 
interpretation of changes in the primary endpoints. In 
an exploratory analysis we tested for a diff erence in the 
proportion of patients reporting an improvement in 
rectal bleeding at 12 months between the two study 
groups using all available questionnaires (ie, the 
CTCAE rectal bleeding questions, rectal LENT SOMA 
objective and management scores, intestinal LENT 
SOMA management score, and EORTC QLQ-CR38 
question 59 “Have you had blood with your stools?”). 
Patients reporting no rectal bleeding at baseline on an 
individual scale were excluded from the analysis of that 
Form to be processed as
Completed after 2-week assessment and less 
than 4·5 months after start of treatment
3-month assessment
Completed 4·5–7·5 months after start of 
treatment
6-month assessment
Completed 7·5–10·5 months after start of 
treatment
9-month assessment
Completed 10·5–14 months after start of 
treatment
12-month assessment
Completed more than 14 months after start 
of treatment
Exclude forms
Table 1: Classifi cation of patient case report forms according to time of 
return after start of treatment
Score of 1 Score of 2 Score of 3 Score of 4
Rectal*
Stool frequency 2–4 per day 5–8 per day >8 per day Uncontrolled 
diarrhoea
Sphincter control Occasional Intermittent Persistent Refractory








Tenesmus Occasional urgency Intermittent urgency Persistent urgency Refractory
Mucosal loss Occasional Intermittent Persistent Refractory
Intestinal†
Stool frequency 2–4 per day 5–8 per day >8 per day Refractory 
diarrhoea
Stool consistency Bulky Loose Mucous, dark, 
watery
··







Constipation 3–4 per week Only twice per week Only once per week No stool in 10 days
LENT SOMA=Late Eff ects in Normal Tissues Subjective, Objective, Management and Analytic scales. 
*The possible range of summed results for the fi ve questions is 0–20, where 0 indicates that no symptoms are 
present and 20 represents the worst possible symptomatology. †The possible range of summed results for the 
four questions is 0–15, where 0 indicates that no symptoms are present and 15 represents the worst possible 
symptomatology (there is no grade 4 stool consistency).
Table 2: Subjective parameter score of the 4-point rectal and intestinal LENT SOMA scoring scales5
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scale. We did two exploratory subgroup analyses of the 
primary endpoints; one analysis considered the group 
of patients who received radiotherapy 1–5 years before 
randomisation, and the other considered the group of 
patients whose trial treatment was delivered by hood 
(or monochamber).
Figure: Trial profi le
IBDQ=modifi ed Infl ammatory Bowel Disease Questionnaire. *Includes one patient in the control group and two patients in the hyperbaric oxygen therapy group who received no treatment.
241 participants screened for eligibility
84 enrolled and randomised
29 assigned to sham control
26 eligible for modified intention-to-treat population
25 suitable for per-protocol population
23 included in intention-to-
 treat analysis of bowel
 component
11 included in intention-to-
 treat analysis of rectal
 bleeding
22  included in per-protocol
 analysis of bowel component
11 included in per-protocol
 analysis of rectal bleeding
55 assigned to hyperbaric oxygen therapy
157 ineligible
 58 did not meet inclusion criteria
 81 declined participation
 5 treated off trial
 1 died
 12 no response
3 excluded
 1 form not returned
 2 returned form off schedule*
3 excluded
 2 missing baseline IBDQ bowel 
  component score
 1 missing 12 month IBDQ bowel 
  component score
15 excluded
 1 missing baseline IBDQ 
  rectal bleeding score
 1 missing 12 month IBDQ 
  rectal bleeding score
 13 baseline IBDQ rectal 
  bleeding score ≥6
1 excluded from per-protocol
 analysis for non-compliance
 because gaps were too long
3 excluded
 2 missing baseline IBDQ bowel 
  component score
 1 missing 12 month IBDQ 
  bowel component score
14 excluded
 1 missing baseline IBDQ 
  rectal bleeding score
 1 missing 12 month IBDQ 
  rectal bleeding score
 12 baseline IBDQ rectal 
  bleeding score ≥6
48 suitable for modified intention-to-treat population
40 suitable for per-protocol population
46 included in intention-to-
 treat analysis of bowel
 component
29 included in intention-to-
 treat analysis of rectal
 bleeding
38 included in per-protocol
 analysis of bowel component
25 included in per-protocol
 analysis of rectal bleeding
7 excluded from intention-to-treat analysis
 4 form not returned*
 3 returned form off schedule
2 excluded
 2 missing baseline IBDQ bowel 
  component score
19 excluded
 19 baseline IBDQ rectal 
  bleeding score ≥6
8 excluded from per-protocol
 analysis for non-compliance
 4 less than 32 pressure exposures
 4 too many gaps or gaps too long
2 excluded
 2 missing baseline IBDQ bowel 
  component score
15 excluded
  15 baseline IBDQ rectal 
  bleeding score ≥6
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We used Stata version 13 for all statistical analyses. The 
trial is registered with the ISRCTN registry, number 
ISRCTN86894066.
Role of funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
report. The corresponding author had full access to all 
the data and had fi nal responsibility for the decision to 
submit for publication.
Results
Between Aug 14, 2009, and Oct 23, 2012, 241 patients 
were given a rigorous initial assessment followed by a 
3-month period of optimised medication. 84 participants 
were considered eligible for trial entry and were 
randomly assigned to treatment with hyperbaric oxygen 
(active treatment group; n=55) or with sham control 
(control group; n=29; fi gure). The trial ended when all 
patients had been followed up for 12 months from start 
of treatment; the fi nal data were collected on 
Oct 28, 2013. Median follow-up was 13∙2 months 
(IQR 12∙4–14∙2). Baseline characteristics of the study 
population are summarised in table 3. There was a 
small imbalance in the proportion of patients reporting 
a medical history of rectal bleeding at trial entry, but 
this was not refl ected in the baseline IBDQ or LENT 
SOMA scales (online case study report). Two-thirds of 
participants had faecal frequency, incontinence, or 
both, symptoms that suggest injury to the colon as well 
as rectum, and a similar proportion reported rectal 
bleeding. 75 (89%) participants received all 40 planned 
pressure exposures, and nine (11%) patients received 
38 exposures or less (one patient received 38 exposures, 
one patient received 31 exposures, one patient received 
18 exposures, one patient received 11 exposures, one 
patient received four exposures, one patient received 
two exposures, and three patients received no 
exposures). Table 4 details the number of IBDQ and 
LENT SOMA assessment forms returned within 
prespecifi ed timeframes.
We found no signifi cant diff erences in the improvement 
of overall bowel function (Mann-Whitney U score 0∙67; 
p=0∙50) or rectal bleeding (U score 1∙69; p=0∙092) after 
12 months between randomised groups (table 5). Of the 
patients in the modifi ed intention-to-treat population  who 
reported slight increase in frequency or worse rectal 
bleeding on IBDQ at baseline, ten (67%) of 15 patients in 
the control group and 26 (74%) of 35 patients in the 
treatment group reported an improvement of at least 
1 point in the IBDQ rectal bleeding score at 12 months 
(absolute diff erence 7∙6% [95% CI –20∙3 to 35∙5]; p=0∙58; 
appendix p 2). Analysis of the IBDQ baseline data did not 
show imbalances in the pattern or severity of symptoms 
between treatment groups (fi gure and appendix p 1).
Sensitivity analyses of both primary endpoints, 
including all data returned for the 12-month timepoint 
irrespective of time of return, showed that the diff erence 
in change from baseline to 12 months between the 
two study groups was consistent with the modifi ed 
intention-to-treat analysis (U score 0∙71 [p=0∙48] for 
overall bowel function; U score 2∙06 [p=0∙040] for rectal 
bleeding). Per-protocol analyses of the primary 
endpoints were also consistent with the modifi ed 






Mean 62·0 (11) 62·3 (11)
Median 63·7 (53·6–69·9) 63·7 (53·9–71·2)
Range 37·3–79·3 34·5–80·9
Sex
Male 14 (48%) 23 (42%)
Female 15 (52%) 32 (58%)
Origin of cancer
Prostate 12 (41%) 21 (38%)
Anus 4 (14%) 4 (7%)
Vagina 3 (10%) 1 (2%)
Cervix 5 (17%) 17 (31%)
Uterus 3 (10%) 8 (15%)
Other* 2 (7%) 4 (7%)
Medical history
Back pain 3 (10%) 7 (13%)
Bloating 18 (62%) 30 (55%)
Constipation 5 (17%) 5 (9%)
Cramps or abdominal pain 14 (48%) 38 (69%)
Diarrhoea 14 (48%) 30 (55%)
Faecal incontinence 19 (66%) 35 (64%)
Frequency 18 (62%) 38 (69%)
Mucus discharge 10 (34%) 21 (38%)
Nausea 4 (14%) 13 (24%)
Other 6 (21%) 8 (15%)
Rectal bleeding 23 (79%) 34 (62%)
Rectal or perineal pain 8 (28%) 10 (18%)
Steatorrhoea 1 (3%) 10 (18%)
Subacute obstructive symptoms 3 (10%) 14 (25%)
Tenesmus 18 (62%) 35 (64%)
Unable to diff erentiate need to 
defecate or pass urine
1 (3%) 2 (4%)
Unable to diff erentiate solid or 
liquid stool
6 (21%) 11 (20%)
Urgency 20 (69%) 48 (87%)
Weight loss 2 (7%) 10 (18%)
Wind 17 (59%) 39 (71%)
Time since pelvic radiotherapy (years)
Median 3·9 (2·5–5·7) 3·5 (2·3–9·7)
Range 1·5–21·2 1·2–34·0
Data are n (%) or median (IQR). *Others were anal canal (n=1) and vulva (n=1) in 
the control group and retroperitoneum (n=1), pelvis (n=1), rectum (n=1), and 
bladder (n=1) in the hyperbaric oxygen therapy group.
Table 3: Patient characteristics at pretrial eligibility assessments
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overall bowel function; U score 1∙44 [p=0·15] for rectal 
bleeding; appendix p 3).
Both treatment groups had a non-signifi cant decrease 
in subjective LENT SOMA scores for rectum and 
intestine indicative of an improvement in symptoms 
(table 6). Sensitivity analyses including all data 
irrespective of specifi ed timelines gave similar results 
(U score 1∙62 [p=0∙11] for rectal LENT SOMA scores; 
U score –1∙41 [p=0∙16] for intestinal LENT SOMA 
scores). Planned descriptive analysis of changes in 
CTCAE grades at baseline, 2 weeks post-treatment, and 
at 12 months also did not show diff erences between the 
treatment groups (appendix p 4). In view of these 
negative results, we did not report the planned 
descriptive analyses of the EORTC QLQ-C30 and 
QLQ-CR38 since they could not aff ect the interpretation 
or conclusions of the trial.
Exploratory analysis comparing patient-reported rectal 
bleeding obtained from the IBDQ questionnaire with 
scores from other scales including the CTCAE rectal 
bleeding, rectal LENT SOMA objective and management, 
intestinal LENT SOMA management, and EORTC 
QLQ-CR38 questionnaires were in line with those 
obtained using IBDQ with the exception of the rectal 
LENT SOMA management score (appendix p 2). 
Five (100%) of fi ve patients in the control group reported 
an improvement in rectal bleeding LENT SOMA 
Management score compared with four (31%) of 
13 patients in the hyperbaric oxygen therapy group. 
Exploratory subgroup analyses of patients who 
completed radiotherapy 1–5 years before entering the 
study did not show any diff erence in IBDQ scores 
between the two groups (U score 0∧59 [p=0∧56] for 
overall bowel function; U score 1·57 [p=0·12] for rectal 
bleeding). Exploratory subgroup analysis in patients 
receiving treatment using a hood or monochamber 
showed no diff erence in overall bowel function but did 
suggest a diff erence in rectal bleeding (U score 
–0·31 [p=0·76] for overall bowel function; U score 
2·9 [p=0·004] for rectal bleeding).
We analysed toxic eff ects in the safety population, 
which included the 81 patients who received at least one 
treatment (53 in the hyperbaric oxygen therapy group 
and 28 in the sham control group). Treatment-emergent 
Baseline 2 weeks 3 months 6 months 9 months 12 months
IBDQ forms returned 84 75 79 78 78 79
IBDQ forms returned* 84 75 68 76 74 74
Rectal LENT SOMA 84 78 ·· ·· ·· 79
Rectal LENT SOMA* 84 78 ·· ·· ·· 72
Intestinal LENT SOMA 84 78 ·· ·· ·· 79
Intestinal LENT SOMA* 84 78 ·· ·· ·· 72
CTCAE 83 78 ·· ·· ·· 79
CTCAE* 83 78 ·· ·· ·· 72
QLQ-C30 84 ·· 77 78 78 79
QLQ-C30* 84 ·· 65 76 75 74
QLQ-CR38 84 ·· 77 78 78 79
QLQ-CR38* 84 ·· 65 76 74 74
IBDQ=Infl ammatory Bowel Disease Questionnaire. LENT SOMA=Late Eff ects in Normal Tissues Subjective, Objective, Management and Analytic scales. CTCAE=Common 
Terminology Criteria for Adverse Events. *Includes only forms returned within the prespecifi ed permissible timeframes detailed in table 1.
Table 4: Overall returns of IBDQ and LENT SOMA assessment forms and those returned within prespecifi ed timeframes
Median score at baseline (IQR) Median score at 12 months 
(IQR)
Median change from baseline 











Bowel function* 51 (44 to 59) 48 (42 to 52) 53 (40 to 59) 51 (36 to 62) 4 (–6 to 9) 3·5 (–3 to 11) 0·67 0·50
Rectal bleeding† 3 (2 to 4) 3 (2 to 4) 4 (2 to 6) 6 (3 to 7) 1 (1 to 2) 3 (1 to 3) 1·69 0·092
Positive changes indicate higher median Infl ammatory Bowel Disease Questionnaire (IBDQ) scores, which signify improvement in symptoms. *Analysis included 23 patients 
in the sham control group and 46 patients in the hyperbaric oxygen treatment group. †Analysis included 11 patients in the sham control group and 29 patients in the 
hyperbaric oxygen treatment group. 40 (47%) of 84 patients scored grade 1–5 (clinically signifi cant) rectal bleeding on the IBDQ bowel function component, compared with 
57 (68%) patients reporting any rectal bleeding in their medical history (panel). 46 (55%) patients had grade 1–3 rectal bleeding at baseline according to Common 
Terminology Criteria for Adverse Events scoring system, and 47 (59%) patients had grade 1–3 rectal bleeding in response to EORTC QLQ-CR38 Question 59. 
Table 5: Median changes in the IBDQ bowel function component and IBDQ rectal bleeding scores from baseline to 12 months in patients assessed within 
10–14 months
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toxic eff ects were reported for 41 (51%) of 81 patients 
receiving at least one treatment in either treatment 
group. The most commonly reported adverse events 
were eye refractive change, including myopia (three [11%] 
of 28 patients in the control group vs 16 [30%] of 
53 patients in the treatment group), increased fatigue or 
tiredness (three [11%] vs two [4%]), and ear pain or 
barotrauma (six [21%] vs 15 [28%]). Eight serious adverse 
events were reported in eight patients: two were reported 
in two patients in the control group (tonsillitis requiring 
surgery [grade 3]; recurrent cancer of the vulva [grade 4]) 
and six serious adverse events were reported in 
six patients in the treatment group (malignant spinal 
cord compression requiring surgery [grade3]; malignant 
paraortic lymph node involvement requiring surgery 
[grade 3]; recurrence of vomiting and dehydration [grade 
3]; diarrhoea and fever associated with Campylobacter 
infection [grade 3]; recurrence of abdominal pain, 
bloating, diarrhoea, and urinary tract infection [grade 3]; 
aneurysm [grade 4]). No reported adverse event was 
considered related to treatment. One patient had an 
improvement in eyesight during treatment. Only two of 
the patients who stopped treatment early did so for 
reasons related to treatment (anxiety). No treatment-
related deaths were noted.
Discussion
Despite some clinical evidence and plausible 
pathophysiological mechanisms justifying an expectation 
of therapeutic eff ect of hyperbaric oxygen therapy, the 
HOT2 trial results detected no clinically relevant benefi t of 
hyperbaric oxygen therapy in individuals with a wide range 
of chronic gastrointestinal dysfunction, including rectal 
bleeding, after curative radiotherapy for pelvic malignancy. 
The modifi ed IBDQ was adopted to assess the primary 
outcome in HOT2, given its successful application in 
characterising patients with gastrointestinal dysfunction 
after pelvic radiotherapy.6,8,11,15–17 None of the exploratory 
analyses using other instruments to measure rectal 
bleeding, including LENT SOMA, CTCAE, and EORTC, 
suggested any clinical benefi t of hyperbaric oxygen.
Pelvic radiation syndrome describes a range of 
physiological disorders that often take a remittent course 
and are best characterised by investigation according to 
structured algorithms before treatment.6 The symptoms 
include pain, bloating, fl atulence, diarrhoea, urgency, 
faecal incontinence, and rectal bleeding. Histologically, 
progressive obliterative endarteritis is a classic feature 
and ischaemic atrophy is an important element of the 
pathophysiology, but direct radiation eff ects on other 
tissue elements, including epithelia, also contribute to 
symptoms.18 The tissues rendered ischaemic by vascular 
atrophy do not share the steep oxygen gradients that 
stimulate angiogenesis in acute surgical wounds unless 
these gradients are artifi cially introduced.19 In studies of 
animal and human skin,20,21 hyperbaric oxygen therapy 
has been shown to restore virtually normal small vessel 
density and transcutaneous oxygen tension after 
high-dose radiotherapy, an eff ect that peaked after 
20–30 treatments in human beings. The proposed 
therapeutic mechanisms include marrow stem-cell 
mobilisation and consequent vasculogenesis, although 
our results do not suggest that these processes, if activated 
by hyperbaric oxygen, were of therapeutic value.22
Our trial results are inconsistent with a long history of 
striking anecdotes and reviews of non-randomised 
studies.2,23–25 A Cochrane intervention review3 identifi ed 
two randomised trials testing hyperbaric oxygen in 
patients with chronic gastrointestinal symptoms after 
pelvic radiotherapy, but the analysis was restricted to the 
HORTIS trial4 because of a high risk of bias identifi ed in 
the other study. The HORTIS trial randomly assigned 
150 patients from Mexico, Turkey, South Africa, and 
Australia with a 3-month or longer medical history of 
radiation proctitis to breathe air at 1∙1 ATA (sham group) 
or 100% oxygen at 2∙0 ATA (active treatment group) for 
90 min for 30 sessions within 6–8 weeks, with an 
additional ten sessions depending on individual 
responses. Improvements in the LENT SOMA score 
(primary endpoint) were found in 120 evaluable patients 
with radiation proctitis; patients in the active treatment 
group recording signifi cantly lower average scores than 
patients in the sham group (p=0∙015), with an estimated 
diff erence of 1∙93 points (95% CI 0∙38–3∙48). The 
HORTIS investigators also reported a signifi cant benefi t 
of hyperbaric oxygen in patients with bowel bother, a 
group of symptoms that include faecal incontinence, 
faecal urgency, and pain. The authors of the Cochrane 






Sham (n=26) Hyperbaric 
oxygen (n=46)
Sham (n=26) Hyperbaric 
oxygen (n=46)
Sham (n=26) Hyperbaric 
oxygen (n=46)
Rectum 6 (5 to 8) 6 (4 to 8) 4·5 (2 to 8) 5 (3 to 8) –1·5 (–4 to 0) –1 (–2 to 1) 1·56 0·12
Intestine 2·5 (1 to 4) 4 (2 to 5) 1 (1 to 4) 2·5 (1 to 4) 0 (–1 to 1) 0 (–2 to 0) –1·30 0·20
High scores indicate worse symptoms; a negative change indicates a lower score at 12 months, signifying improvement in function. LENT SOMA=Late Eff ects in Normal 
Tissues Subjective, Objective, Management and Analytic scale. 46 (55%) patients had grade 1–4 rectal bleeding at baseline as assessed by the LENT SOMA scale. 
Table 6: Median changes in LENT SOMA aggregate parameter scores for rectum and intestine from baseline to 12 months in patients assessed within 
10–14 months
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review interpreted these results as non-signifi cant and 
sensitive to randomised patients excluded from primary 
analysis but concluded that HORTIS supported the 
continued use of hyperbaric oxygen for patients with 
radiation proctitis.
It is unclear why the results of HOT2 fail to reproduce 
the HORTIS4 fi ndings. Although a single-centre study in 
terms of patient referral and selection, HOT2 trial 
participants were treated at one of ten UK-registered 
hyperbaric facilities. Patient selection was unusually 
rigorous, including assessment by a gastroenterologist 
specialised in radiation enteropathy and a 3-month run-in 
period of optimised oral drug treatment to ensure that 
eligible patients had radiation-induced symptoms that 
could not be controlled by standard measures. The trial 
population is considered representative of patients with 
radiation enteropathy in terms of their symptoms, 
although patients with severe faecal incontinence or 
transfusion-dependent rectal bleeding are likely to be 
under-represented, the former being too restricted to leave 
their homes and the latter considered too seriously at risk 
to be considered by their primary physicians for entry into 
a trial with a sham treatment option. We assessed 
20 characteristics relating to bowel dysfunction at baseline, 
and despite small imbalances in the proportion of patients 
with a medical history of rectal bleeding (23 [79%] of 
29 patients in the control group vs 34 [62%] of 55 patients 
in the treatment group), this imbalance did not apply to 
baseline IBDQ rectal bleeding scores analysed as the 
primary endpoint. In other respects, symptom duration in 
HOT2, at a median 3∙7 years (IQR 2∙4–6∙8) post-
radiotherapy, is consistent with that of the HORTIS 
population, and HOT2 patient characteristics are well 
balanced between randomised groups.
In a literature review26 of ten retrospective studies 
published between 1960 and 2004 reporting favourable 
results of hyperbaric oxygen therapy for patients with 
radiation proctitis, patients had an average of 
24 treatments each. The randomised, sham-controlled 
HORTIS trial4 reported benefi cial clinical eff ects of 
hyperbaric oxygen after 30–40 treatments. Hence, the 
40 treatments used in HOT2 can be considered an 
appropriate test of hyperbaric oxygen. Compliance with 
treatment in HOT2 was reasonably high, with 75 (88%) 
of 84 patients eligible for inclusion in the intention-to-treat 
population, as required by the analysis plan. Post-hoc 
analyses in the per-protocol population failed to detect 
any treatment eff ect. Pre-trial investigations designed to 
exclude patients with residual malignant disease ensured 
that only three patients developed cancer recurrence 
while participating in the study.
Other relevant points of diff erence between the HORTIS4 
and HOT2 trials include the immediate post-treatment 
timepoint for the primary analysis in HORTIS, compared 
with the primary analysis at 12 months post-treatment in 
HOT2. Exploratory analyses of the 2-week post-treatment 
eff ects in HOT2 showed no diff erence between 
randomised groups for any of the primary or secondary 
endpoints. This included change in total LENT SOMA 
score, which was the primary endpoint analysed by the 
HORTIS investigators. Unlike HOT2, in which we 
analysed the primary endpoint in a modifi ed 
intention-to-treat population, the primary analysis in 
HORTIS excluded 30 of 150 randomised patients who did 
not complete the treatment protocol (plus one patient lost 
to follow-up), although unplanned analyses of the 
outcomes of clinical assessments by intention-to-treat 
were also consistent with a benefi cial eff ect of hyperbaric 
oxygen in HORTIS. In other exploratory analyses of HOT2 
endpoints (including subgroup analysis of patients 
completing radiotherapy 1–5 years before randomisation 
and subgroup analysis of patients receiving treatment by 
hood or hyperbaric chamber rather than mask), we could 
not identify variables that might explain diff erences 
in reported outcomes between these two trials. 
Randomisation appears to have resulted in a reasonably 
even distribution of patient characteristics between the 
treatment and control groups in our study, to the extent 
that the total eff ect of these covariates would not be 
expected to mask any eff ect of hyperbaric oxygen. The very 
small number of patients with transfusion-dependent 
rectal bleeding in this study prevents us from commenting 
on the use of hyperbaric oxygen therapy for patients 
referred for this potentially life-threatening complication.
Our trial was designed to have a power of 80%; with 
69 evaluable patients, we had a power of about 75% to 
detect a diff erence of the magnitude expected in the fi rst 
of the primary endpoints. We did not detect a clinically 
or statistically signifi cant clinical benefi t of hyperbaric 
oxygen therapy for patients with chronic gastrointestinal 
dysfunction, including rectal bleeding, after pelvic 
radiotherapy. The fi ndings contrast with previous 
reports, highlighting an urgent need for more level 1 
evidence to determine with confi dence whether 
hyperbaric oxygen therapy can be recommended as a 
standard of care for this group of patients.
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